Alpha-1 Foundation
-
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy
Malvern-based Ocugen has been granted rare pediatric disease designation by the Food and Drug Administration for its experimental gene therapy targeting Stargardt disease, writes John…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
